José M. Vega, M.D. Joins Moderna as Chief Safety Officer
January 12 2021 - 8:00AM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines, today announced
that José M. Vega, M.D. joined Moderna as Chief Safety Officer
effective Monday, January 11, 2021. Dr. Vega will report to Chief
Medical Officer Tal Zaks, M.D., Ph.D.
“José brings a strategic level of leadership and deep experience
in drug development and pharmacovigilance in global
biopharmaceutical companies including Merck and Amgen,” said Dr.
Zaks. “I am thrilled to welcome José to the Moderna team as we
enter the next phase of growth of our company.”
Dr. Vega joins Moderna from Merck (NYSE: MRK) where he led the
Global Clinical Safety and Pharmacovigilance organization and
served as the Chief Safety Officer for Merck Research Laboratories
(MRL) since 2013. In this role, he led a global team of nearly 600
safety and pharmacovigilance professionals in Clinical Safety Risk
Management, Medical Safety Review, Global Pharmacovigilance, and
the EU Qualified Person for Pharmacovigilance (QPPV) groups.
Prior to Merck, Dr. Vega spent 10 years at Amgen (Nasdaq: AMGN),
where he held the role of Vice President, Global Safety for more
than 5 years and led global efforts for safety signal detection and
assessment, pharmacovigilance, pharmacoepidemiology, and
therapeutic area safety. Upon joining Amgen in 2003, Dr. Vega led
the Proof of Concept Group in Early Development and served for
several years as the Vice President and Therapeutic Area Head for
General Medicine in Global Clinical Development.
Between 1997 and 2003, Dr. Vega served in roles of increasing
responsibility at Merck Research Laboratories, initially in
Clinical Pharmacology and then in the role of Senior Director in
Clinical Drug Metabolism. Prior to joining Merck, Dr. Vega
practiced and taught at the Massachusetts General Hospital and
Harvard Medical School as an emergency department attending
physician for 5 years and as part of an academic primary care and
internal medicine practice for more than 2 years.
“I am delighted to join Moderna and look forward to supporting
its mission to deliver on the promise of mRNA science to create a
new generation of transformative medicines for patients by
fulfilling our uncompromising commitment to patient safety and
ensuring the highest standards of quality and compliance,” said Dr.
Vega.
Dr. Vega has been a member of the Clinical Trials Transformation
Initiative (CTTI) Steering Committee since 2008, representing Amgen
from 2008 to 2013 and Merck since 2014. He has been a member of the
TransCelerate Pharmacovigilance Steering Committee since 2016 and
chaired the committee from 2016 to 2018.
Dr. Vega received a B.A. in Biochemical Sciences summa cum laude
from Harvard College and an M.A. in Biochemistry and Molecular
Biology from Harvard University. Dr. Vega received his M.D. degree
from Harvard Medical School and completed his internal medicine
internship and residency at Massachusetts General Hospital.
About Moderna
In 10 years since its inception, Moderna has transformed from a
science research-stage company advancing programs in the
promising-but-still-unproven field of messenger RNA (mRNA), to an
enterprise with its first medicine having treated millions of
people, a diverse clinical portfolio of vaccines and therapeutics
across six modalities, a broad intellectual property portfolio in
areas including mRNA and lipid nanoparticle formulation, and an
integrated manufacturing plant that allows for both clinical and
commercial production at scale and at unprecedented speed. Moderna
maintains alliances with a broad range of domestic and overseas
government and commercial collaborators, which has allowed for the
pursuit of both groundbreaking science and rapid scaling of
manufacturing. Most recently, Moderna’s capabilities have come
together to allow the authorized use of one of the earliest and
most-effective vaccines against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases and auto-immune diseases. Today, 24 development programs
are underway across these therapeutic areas, with 13 programs
having entered the clinic. Moderna has been named a top
biopharmaceutical employer by Science for the past six years. To
learn more, visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210112005350/en/
Moderna Contacts
Media: Colleen Hussey Director, Corporate Communications
617-335-1374 Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Senior Vice President &
Head of Investor Relations 617-209-5834
Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024